Today: 9 June 2026
Browse Category

OTC:FLYYQ 23 November 2025 - 7 December 2025

Spirit Airlines Stock in December 2025: What SAVEQ and FLYYQ Investors Need to Know After the Second Bankruptcy

Spirit Airlines Stock in December 2025: What SAVEQ and FLYYQ Investors Need to Know After the Second Bankruptcy

Spirit Airlines stock now trades over-the-counter under SAVEQ and FLYYQ after two Chapter 11 bankruptcies within a year. SAVEQ last changed hands near $0.47, while FLYYQ trades around $0.31 with low liquidity. The company was delisted from major exchanges after failed merger talks and ongoing financial losses. Existing shareholders are not expected to recover value under the latest restructuring plan.
7 December 2025
···
Spirit Airlines Stock (FLYYQ) on November 23, 2025: Price, Second Bankruptcy, Class Actions and What Investors Need to Know

Spirit Airlines Stock (FLYYQ) on November 23, 2025: Price, Second Bankruptcy, Class Actions and What Investors Need to Know

Spirit Aviation Holdings (OTC: FLYYQ), parent of Spirit Airlines, traded at $0.25 per share Sunday, valuing the company at about $6.7 million after two Chapter 11 filings this year. Law firm Bronstein, Gewirtz & Grossman renewed calls for shareholders with losses to seek lead-plaintiff status in a class-action suit before a December 1 deadline. No new company press releases or SEC filings were issued today.
23 November 2025
···

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop